<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699387</url>
  </required_header>
  <id_info>
    <org_study_id>CHAGAS-CHILDREN-POPPK</org_study_id>
    <nct_id>NCT00699387</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Benznidazole in Children With Chagas Disease</brief_title>
  <official_title>Population Pharmacokinetics Study of Benznidazole in Children With Chagas Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Bunge y Born (Argentina)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional de La Plata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consejo de Investigacion en Salud Gobierno de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Niños R. Gutierrez de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Chagas disease is a parasitic infection caused by the Trypanosome cruzi. The
      initial phase of the infection happens mainly in children. Up to 10% of infected children
      die. Survivors often develop chronic infection leading to heart disease and other
      complications in 30% of patients. These complications often result in death or severe
      handicaps in early adulthood, depriving societies of individuals in their most productive
      years.

      There are 20 million people infected in Latin America. Complications lead to 20,000 deaths
      every year.

      Treatment during the acute phase with benznidazole leads to a high cure rate. However, there
      are very few studies of this drug and virtually none in children, even though benznidazole
      was developed over 30 years ago.

      Hypotheses and Specific Aims: We hypothesize that the pharmacokinetics of benznidazole in
      children is different from adults, and that obtaining information on how it is absorbed,
      distributed and eliminated in children will allow optimization of treatment of Chagas disease
      in this population. This will in turn improve the outlook for children by reducing mortality
      and long term complications. We aim to study the pharmacokinetics of benznidazole in children
      receiving the drug for treatment of Chagas disease, and to correlate it with treatment
      effectiveness and incidence of adverse effects.

      Potential Impact: This novel knowledge will allow better and more rational approaches to the
      treatment of Chagas disease. It will also set the foundation for further studies that will be
      able to test improved therapies that may increase treatment response in vulnerable children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of Population pharmacokinetics parameters of benznidazole (i.e. median population clearance, absorption and volume of distribution, and their respective inter-individual variabilities)</measure>
    <time_frame>2 months (treatment period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 months (treatment period)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of pediatric Chagas disease with benznidazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <other_name>Children with Chagas Disease Treated with Benznidazole</other_name>
    <other_name>Niños con Chagas en Tratamiento con Benznidazol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 2 - 12 years old of both sexes, with a diagnosis of Chagas' disease and
             eligible for treatment with benznidazole, as per current treatment protocols.

          -  Chagas disease diagnostic criteria: At least 2 positive serological tests for
             Trypanosoma cruzi infection (ELISA, hemoagglutination, particle agglutination tests).

          -  Informed consent signed by the parents, and consent or assent of the patients
             (according to age and consenting capacity).

        Exclusion Criteria:

          -  Patients with a history of hypersensitivity to benznidazole or any of the drug
             excipients

          -  Immunocompromised patients

          -  Altered hepatic function (increase in AST/ALT x3 or bilirubin x3) or altered renal
             function (increase in creatinine x3)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Altcheh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Parasitology Service, Children's Hospital &quot;R. Gutierrez&quot; of Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Facundo Garcia Bournissen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Clinical Pharmacology &amp; Toxicology, Hospital for Sick Children, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norberto Giglio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epidemiology Service, Children's Hospital &quot;R. Gutierrez&quot; of Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gideon Koren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Clinical Pharmacology &amp;Toxicology, Hospital for Sick Children, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar Della Vedova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Nacional de La Plata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido Mastrantonio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facultad de Ciencias Exactas, Universidad Nacional de La Plata</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parasitology Division, Children's Hospital &quot;R Gutierrez&quot; of Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>July 29, 2011</last_update_submitted>
  <last_update_submitted_qc>July 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Jaime Altcheh</name_title>
    <organization>Servicio de Parasitología, Hospital de Niños &quot;R Gutiérrez&quot; de Buenos Aires</organization>
  </responsible_party>
  <keyword>Chagas disease</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>benznidazole</keyword>
  <keyword>population pharmacokinetics</keyword>
  <keyword>neglected diseases</keyword>
  <keyword>parasitology</keyword>
  <keyword>pediatric clinical pharmacology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

